In in vitro and ex vivo studies in SF3B1-mutated AML, SF3B1 modulators have shown potential as novel therapeutic targets in FLT3-internal tandem duplication (ITD) AML cells with a high allelic ratio and/or long ITD length [53]. Here, FLT3 is linked to acute myeloid leukemia.